{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T18:45:54Z","timestamp":1785869154670,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013348","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000}}],"reference-count":164,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013348.pub2","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T14:49:12Z","timestamp":1614869352000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Yunhai","family":"Chuai","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China"},{"name":"Department of Obstetrics and Gynaecology; Sixth Medical Centre, Chinese PLA General Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Rizzuto","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; Royal Brisbane and Women\u2019s Hospital; Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China"},{"name":"Department of Oncology; Fifth Medical Centre, Chinese PLA General Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China"},{"name":"Department of Oncology; Fifth Medical Centre, Chinese PLA General Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China"},{"name":"Department of Oncology; Fifth Medical Centre, Chinese PLA General Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J","family":"Otter","sequence":"additional","affiliation":[{"name":"Oncology; Royal Surrey County Hospital; Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasiah","family":"Bharathan","sequence":"additional","affiliation":[{"name":"Department of Gynaecological Oncology; University Hospitals of Leicester NHS Trust, Leicester General Hospital; Leicester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Stewart","sequence":"additional","affiliation":[{"name":"Oncology; Royal Surrey County Hospital; Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital, Medical School of Chinese PLA; Beijing China"},{"name":"Department of Obstetrics and Gynaecology; Sixth Medical Centre, Chinese PLA General Hospital; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"10.1002\/14651858.CD013348.pub2-BIB0001|cit1","unstructured":"A prospective randomized controlled trial for apatinib mesylate combined with chemotherapy or concurrent chemoradiotherapy in the treatment of first recurrence or untreated cervical cancer in IVB stage Chinese Clinical Trial Registry"},{"issue":"11","key":"10.1002\/14651858.CD013348.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"e19372","DOI":"10.1097\/MD.0000000000019372","article-title":"Apatinib combined with chemotherapy or concurrent chemobrachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study","volume":"99","author":"Guo","year":"2020","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0003|cit3","unstructured":"A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced\/recurrent disease EU Clinical Trials Register"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013348.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/jco.2009.27.15_suppl.5520","article-title":"A randomized phase II study: pazopanib (P) versus lapatinib (L) versus combination of pazopanib\/lapatinib (L plus P) in advanced and recurrent cervical cancer (CC)","volume":"27","author":"Monk","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"22","key":"10.1002\/14651858.CD013348.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1200\/JCO.2009.26.9571","article-title":"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer","volume":"28","author":"Monk","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"36","key":"10.1002\/14651858.CD013348.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1200\/JCO.2011.38.8777","article-title":"Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer","volume":"29","author":"Monk","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0007|cit7","unstructured":"Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0008|cit8","unstructured":"A phase II, open-label, randomized, multicenter trial of pazopanib (GW786034) in combination with lapatinib (GW572016) compared to pazopanib montherapy and lapatinib monotherapy in subjects with FIGO stage IVB or recurrent or persistent cervical cancer with zero or one prior chemotherapy regimen for advanced\/recurrent disease GSK Clinical Study Register"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0009|cit9","unstructured":"CIRCCa (Cediranib In Recurrent Cervical Cancer): a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic\/recurrent cervical cancer EU Clinical Trials Register"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0010|cit10","unstructured":"CIRCCa (Cediranib In Recurrent Cervical Cancer): a trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic\/recurrent cervical cancer ISCRTN Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0011|cit11","unstructured":"Carboplatin and paclitaxel with or without cediranib maleate in treating patients with metastatic or recurrent cervical cancer that cannot be removed by surgery ClinicalTrials.gov"},{"issue":"15","key":"10.1002\/14651858.CD013348.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S1470-2045(15)00220-X","article-title":"Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Symonds","year":"2015","journal-title":"Lancet Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013348.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/bcp.13965","article-title":"Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients","volume":"85","author":"Zhou","year":"2019","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0014|cit14","unstructured":"Randomized phase III trial of cisplatin plus paclitaxel with and without bevacizumab versus doublet without platinum, topotecan plus paclitaxel, with and without bevacizumab, in stage IVb, recurrent or persistent carcinoma of the cervix EU Clinical Trials Register"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0015|cit15","article-title":"Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study","volume":"pii: ijgc-2019-","author":"Chase","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013348.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ygyno.2015.01.064","article-title":"Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Eskander","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD013348.pub2-BIB0017|cit17","first-page":"241","article-title":"A trial-based economic assessment of bevacizuamb and chemotherapy versus chemotherapy alone for advanced cervical cancer: cost-effective analysis of Gynecologic Oncology Group (GOG) protocol 240","volume":"23","author":"Minion","year":"2013","journal-title":"International Journal of Gynecological Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2015.02.027","article-title":"A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer","volume":"137","author":"Minion","year":"2015","journal-title":"Gynecologic Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0019|cit19","unstructured":"Paclitaxel and cisplatin or topotecan with or without bevacizumab in treating patients with stage IVB, recurrent, or persistent cervical cancer ClinicalTrials.gov"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013348.pub2-BIB0020|cit20","first-page":"S18","article-title":"Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: a Gynecologic Oncology Group study","volume":"49","author":"Penson","year":"2013","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD013348.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2013.31.15_suppl.3","article-title":"Incorporation of bevacizumab in the treatment of recurrent and metastatic cervical cancer: a phase III randomized trial of the Gynecologic Oncology Group","volume":"31","author":"Tewari","year":"2013","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013348.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2014.03.163","article-title":"Prospective validation of pooled clinical prognostic factors in patients with recurrent and advanced cervical cancer: a Gynecologic Oncology Group (GOG) study","volume":"133","author":"Tewari","year":"2014","journal-title":"Gynecologic Oncology"},{"issue":"8","key":"10.1002\/14651858.CD013348.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD013348.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.1158\/1078-0432.CCR-15-1346","article-title":"Prospective validation of pooled prognostic factors in women with advanced cervical cancer treated with chemotherapy with\/without bevacizumab: NRG Oncology\/GOG Study","volume":"21","author":"Tewari","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"10103","key":"10.1002\/14651858.CD013348.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD013348.pub2-BIB0027|cit27","first-page":"LBA26","article-title":"Final overall survival analysis of the phase III randomized trial of chemotherapy with and without bevacizumab for advanced cervical cancer: an NRG Oncology-Gynecologic Oncology Group study","volume":"25","author":"Tewari","year":"2014","journal-title":"Annals of Oncology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013348.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2015.01.358","article-title":"Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology\/Gynecologic Oncology Group study","volume":"137","author":"Waggoner","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD013348.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s12094-017-1808-x","article-title":"Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in \"real world\" patients","volume":"20","author":"Godoy-Ortiz","year":"2018","journal-title":"Clinical and Translational Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0030|cit30","unstructured":"Chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus chemotherapy plus paclitaxel and bevacizumab in carcinoma of the cervix EU Clinical Trials Register (accessed 2 December 2019)"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ijgc-2019-000880","article-title":"A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10\/GEICO 68-C\/JGOG1084\/GOG-3030)","volume":"30","author":"Grau","year":"2020","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0032|cit32","unstructured":"A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc) Japan Registry of Clinical Trials"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0033|cit33","unstructured":"A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix (BEATcc) ClinicalTrials.gov"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013348.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"TP5594","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5594","article-title":"BEATcc (ENGOT-Cx10\/GEICO 68-C\/GOG3030\/JGOG1084): a randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m\/r) carcinoma of the cervix (CCx)","volume":"37","author":"Oaknin","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0035|cit35","unstructured":"Randomised phase II trial of cediranib and olaparib maintenance in advanced\/recurrent cervical cancer (COMICE) EU Clinical Trials Register"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0036|cit36","unstructured":"COMICE: a randomised double blind placebo controlled phase II clinical trial of cediranib and olaparib maintenance in advanced\/recurrent cervical cancer ISRCTN Registry"},{"issue":"12","key":"10.1002\/14651858.CD013348.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jjco\/hyy137","article-title":"A randomized phase II\/III trial of conventional paclitaxel and carboplatin with or without bevacizumab vs dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent or persistent cervical carcinoma: Japan Clinical Oncology Group Study (JCOG1311)","volume":"48","author":"Ishikawa","year":"2018","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0038|cit38","unstructured":"Randomized phase II\/III trial of conventional paclitaxel and carboplatin with\/without bevacizumab versus dose-dense paclitaxel and carboplatin with\/without bevacizumab in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311, CC-TC\/ddTC-P2\/3) Japan Registry of Clinical Trials"},{"issue":"15","key":"10.1002\/14651858.CD013348.pub2-BIB0039|cit39","first-page":"Suppl 1","article-title":"A randomized phase II\/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311)","volume":"Conference: 201","author":"Kitagawa","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD013348.pub2-BIB0040|cit40","first-page":"89","article-title":"KEYNOTE-826: a phase III randomized study of chemotherapy with or without pembrolizumab for first-line treatment of persistent, recurrent, or metastatic cervical cancer","volume":"30","author":"Fujiwara","year":"2019","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0041|cit41","unstructured":"Efficacy and safety study of first-line treatment with pembrolizumab (MK-3475) plus chemotherapy versus placebo plus chemotherapy in women with persistent, recurrent, or metastatic cervical cancer (MK-3475-826\/KEYNOTE-826) ClinicalTrials.gov"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD013348.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"TP5595","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5595","article-title":"KEYNOTE826: a phase 3, randomized, double blind, placebo controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer","volume":"37","author":"Shapira-Frommer","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013348.pub2-BIB0043|cit43","first-page":"A162","article-title":"KEYNOTE-826: a phase 3, randomized, double blind, placebo-controlled study of pembrolizumab plus chemotherapy for first line treatment of persistent, recurrent, or metastatic cervical cancer","volume":"29","author":"Tewari","year":"2019","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0044|cit44","unstructured":"Efficacy and safety of BCD-100 (anti-PD-1) in combination with platinum-based chemotherapy with and without bevacizumab as first-line treatment of subjects with advanced cervical cancer (FERMATA) ClinicalTrials.gov"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ygyno.2014.11.003","article-title":"Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?","volume":"136","author":"Phippen","year":"2015","journal-title":"Gynecologic Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013348.pub2-BIB0046|cit46","first-page":"767","article-title":"Clinical efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of advanced cervical cancer (Chinese)","volume":"8","author":"Rao","year":"2018","journal-title":"Anti-tumor Pharmacy"},{"issue":"5","key":"10.1002\/14651858.CD013348.pub2-BIB0047|cit47","first-page":"455","article-title":"Efficacy of bevacizumab combined with cisplatin chemotherapy and definitive radiotherapy in treatment of advanced cervical adenocarcinoma (Chinese)","volume":"31","author":"Xie","year":"2016","journal-title":"Journal of Practical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0048|cit48","unstructured":"A phase II prospective, multicenter, randomized controlled trial for maintenance therapy of apatinib combined with capecitabine for recurrent\/metastatic and persistent cervical cancer after chemoradiotherapy Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0049|cit49","unstructured":"First-line chemotherapy combined with or without apatinib in patients with primary recurrence of cervical cancer Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0050|cit50","unstructured":"Aapatinib plus paclitaxel and cisplatin\/carboplatin versus paclitaxel and cisplatin\/carboplatin in the treatment of stage IVB, recurrent or persistent cervical cancer: a prospective, randomized, multicenter, phase II clinical study Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0051|cit51","unstructured":"Phase II clinical study for anlotinib combined with gemcitabine in the treatment of recurrent or metastatic advanced cervical cancer Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0052|cit52","unstructured":"A prospective, exploratory, single-center clinical study for anlotinib hydrochloride combined with chemotherapy versus chemotherapy alone for advanced, recurrent, and persistent vaginal cancer, cervical cancer, and uterine malignancies Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0053|cit53","unstructured":"Efficacy and safety of carillizumab combined with apatinib mesylate and concurrent chemoradiotherapy in the treatment of IVB cervical cancer Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0054|cit54","unstructured":"A randomized, controlled and open clinical study for TC regimen, TC regimen combined with apatinib or TC regimen combined with SHR-1210 in the treatment of advanced and recurrent cervical cancer Chinese Clinical Trial Registry"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0055|cit55","unstructured":"ENGOT-cx1\/BGOG-cx1. \"Randomized double-blind Phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma\" EU Clinical Trials Register"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0056|cit56","unstructured":"BGOG-cx1\/ENGOT-cx1. Randomized double-blind phase II study comparing 3-weekly carboplatin + paclitaxel with or without concomitant and maintenance nintedanib (NINTEDANIB) in advanced or recurrent cervical carcinoma ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0057|cit57","unstructured":"The efficacy and safety of apatinib as second-line for advanced recurrent cervical cancer (AARCA) Chinese Clinical Trial Registry"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s13063-018-2858-2","article-title":"Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial","volume":"19","author":"Zhou","year":"2018","journal-title":"Trials"},{"issue":"5","key":"10.1002\/14651858.CD013348.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"Journal of the National Cancer Institute"},{"issue":"5","key":"10.1002\/14651858.CD013348.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.2015-0393","article-title":"Clinical trials of antiangiogenesis therapy in recurrent\/persistent and metastatic cervical cancer","volume":"21","author":"Alldredge","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Global Health"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ygyno.2007.04.028","article-title":"Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for cetuximab-mediated therapy in recurrent\/metastatic disease","volume":"106","author":"Bellone","year":"2007","journal-title":"Gynecologic Oncology"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0063|cit63","first-page":"477","article-title":"Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004","journal-title":"Canadian Medical Association Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013348.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ijgo.12611","article-title":"Cancer of the cervix uteri","volume":"143","author":"Bhatla","year":"2018","journal-title":"International Journal of Gynaecology and Obstetrics"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ijgo.12749","article-title":"Revised FIGO staging for carcinoma of the cervix uteri","volume":"145","author":"Bhatla","year":"2019","journal-title":"International Journal of Gynecology & Obstetrics"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0066|cit66","first-page":"4032","article-title":"Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy","volume":"56","author":"Borgstrom","year":"1996","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O","article-title":"Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumours in vivo","volume":"35","author":"Borgstrom","year":"1998","journal-title":"Prostate"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0068|cit68","first-page":"4203","article-title":"Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin","volume":"19","author":"Borgstrom","year":"1999","journal-title":"Anticancer Research"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0069|cit69","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"11","key":"10.1002\/14651858.CD013348.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0071|cit71","unstructured":"Cancer Research UK Incidence of cervical cancer www.cruk.org.uk"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0072|cit72","volume-title":"China Gynaecological Oncology. 1st edition","author":"Cao","year":"2011"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0073|cit73","volume-title":"Chinese Obstetrics and Gynecology. 3rd edition","author":"Cao","year":"2014"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0074|cit74","volume-title":"Cervical Carcinoma","author":"Cao","year":"2017"},{"issue":"132","key":"10.1002\/14651858.CD013348.pub2-BIB0075|cit75","first-page":"1","article-title":"Prognostic role of pretreatment thrombocytosis on survival in patients with cervical cancer: a systematic review and meta-analysis","volume":"17","author":"Cao","year":"2019","journal-title":"World Journal of Surgical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0077|cit77","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Annals of the Academy of Medicine Singapore"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0078|cit78","unstructured":"National Cancer Institute Common terminology criteria for adverse events (CTCAE) v5.0 https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0079|cit79","volume-title":"Systematic Reviews in Health Care: Meta-Analysis in Context","author":"Deeks","year":"2001"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0080|cit80","first-page":"105","article-title":"Association of tumour induced vascularization with clinicopathological parameters in cervical neoplasm","volume":"11","author":"Dellas","year":"1997","journal-title":"International Journal of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"10.1002\/14651858.CD013348.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/bjc.1997.571","article-title":"Angiogenesis is associated with vascular endothelial growth factor expression in cervical intraepithelial neoplasia","volume":"76","author":"Dobbs","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0083|cit83","first-page":"1","article-title":"Palliative interventions for controlling vaginal bleeding in advanced cervical cancer (Review)","volume":"3","author":"Eleje","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nature Reviews. Cancer"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/1758834014543794","article-title":"Targeting angiogenesis in advanced cervical cancer","volume":"6","author":"Eskander","year":"2014","journal-title":"Therapeutic Advances in Medical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01300","article-title":"Evolution of cancer pharmacological treatments at the turn of the third millennium","volume":"9","author":"Falzone","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0087|cit87","article-title":"Radical hysterectomy after chemoradiation in FIGO stage III cervical cancer patients versus chemoradiation and brachytherapy: complications and 3 years survival","volume":"24","author":"Fanfani","year":"2016","journal-title":"European Journal of Surgical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"International Journal of Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","article-title":"What is the evidence that tumors are angiogenesis dependent?","volume":"82","author":"Folkman","year":"1990","journal-title":"Journal of the National Cancer Institute"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2015.05.009","article-title":"Antiangiogenic agents in gynecological cancer: state of art and perspectives of clinical research","volume":"96","author":"Gadducci","year":"2015","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"9","key":"10.1002\/14651858.CD013348.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007930.pub2","article-title":"Angiogenesis inhibitors for the treatment of ovarian cancer","author":"Gaitskell","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0093|cit93","unstructured":"Full prescribing information: Avastin (bevacizumab) injection for intravenous use Available from https:\/\/www.gene.com\/download\/pdf\/avastin_prescribing.pdf"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0094|cit94","first-page":"1388","article-title":"Cervical cancer","volume":"8","author":"Greer","year":"2010","journal-title":"Journal of the National Cancer Institute"},{"issue":"8","key":"10.1002\/14651858.CD013348.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/cncr.22217","article-title":"The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24","volume":"107","author":"Greimel","year":"2006","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting angiogenesis: progress with anti-VEGF treatment with large molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jnci\/86.8.614","article-title":"Microvessel density and distribution in ductal carcinoma in situ of the breast","volume":"86","author":"Guidi","year":"1994","journal-title":"Journal of the National Cancer Institute"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: introduction to GRADE evidence profiles and summary of findings","volume":"64","author":"Gyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"357","author":"Higgins","year":"2003","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org\/handbook","DOI":"10.1002\/9781119536604"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study","volume":"17","author":"Huang","year":"2007","journal-title":"International Journal of Gynecological Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0104|cit104","unstructured":"Cancer incidence www.idsscotland.org\/health-topics\/cancer\/publications\/index.asp"},{"issue":"10043","key":"10.1002\/14651858.CD013348.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1002\/14651858.CD013348.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","article-title":"Tumor angiogenesis","volume":"358","author":"Kerbel","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013348.pub2-BIB0107|cit107","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008218.pub3","article-title":"Antiangiogenic therapy for high-grade glioma","author":"Khasraw","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"362","key":"10.1002\/14651858.CD013348.pub2-BIB0108|cit108","first-page":"6423","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"29","author":"Kim","year":"1993","journal-title":"Nature"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1525-1438.2000.010004305.x","article-title":"Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection","volume":"10","author":"Kim","year":"2000","journal-title":"International Journal of Gynecological Cancer"},{"issue":"19","key":"10.1002\/14651858.CD013348.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","article-title":"Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505","volume":"33","author":"Kitagawa","year":"2015","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clinthera.2014.11.012","article-title":"Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer","volume":"37","author":"Krill","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/2046-4053-2-81","article-title":"Assessing and presenting summaries of evidence in Cochrane Reviews","volume":"23","author":"Langendam","year":"2013","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"21","key":"10.1002\/14651858.CD013348.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study","volume":"23","author":"Bundy","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12032-017-0972-8","article-title":"Antiangiogenics and immunotherapies in cervical cancer: an update and future's view","volume":"34","author":"Luvero","year":"2017","journal-title":"Medical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2009.08.012","article-title":"A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND 184","volume":"116","author":"Mackay","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD013348.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1093\/annonc\/mdx220","article-title":"Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Marth","year":"2017","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3802\/jgo.2015.26.1.3","article-title":"Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors","volume":"26","author":"Matsuo","year":"2015","journal-title":"Journal of Gynecologic Oncology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/2046-4053-3-82","article-title":"A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation","volume":"3","author":"Meader","year":"2014","journal-title":"Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijrobp.2015.09.009","article-title":"Sorafenib increases tumor hypoxia in cervical cancer patients treated with radiation therapy: results of a Phase 1 clinical study","volume":"94","author":"Milosevic","year":"2016","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14737140.2016.1246187","article-title":"The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer","volume":"17","author":"Minion","year":"2017","journal-title":"Expert Review of Anticancer Therapy"},{"issue":"7","key":"10.1002\/14651858.CD013348.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1200\/JCO.2008.18.9043","article-title":"Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"28","key":"10.1002\/14651858.CD013348.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynaecological Oncology Group study","volume":"27","author":"Monk","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"25","key":"10.1002\/14651858.CD013348.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1200\/JCO.2014.56.8733","article-title":"Evidence-based therapy for recurrent cervical cancer","volume":"32","author":"Monk","year":"2014","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD013348.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/01.cco.0000239893.21161.51","article-title":"Chemotherapy for recurrent cervical carcinoma","volume":"18","author":"Moore","year":"2006","journal-title":"Current Opinions in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ygyno.2009.09.006","article-title":"Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study","volume":"116","author":"Moore","year":"2010","journal-title":"Gynecologic Oncology"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0127|cit127","first-page":"934","article-title":"Pelvic exenteration, University of Michigan: 100 patients at 5 years","volume":"74","author":"Morley","year":"1989","journal-title":"Obstetrics and Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/pbc.23159","article-title":"Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program","volume":"58","author":"Morton","year":"2012","journal-title":"Pediatric Blood and Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1146\/annurev.pathol.2.010506.134925","article-title":"VEGF-A and the induction of pathological angiogenesis","volume":"2","author":"Nagy","year":"2007","journal-title":"Annual Review of Pathology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0130|cit130","unstructured":"NCCN Clinical Practice Guidelines in Oncology Cervical cancer www.nccn.org\/professionals\/physician_gls\/default.aspx#site"},{"issue":"24","key":"10.1002\/14651858.CD013348.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1470-2045(15)70004-5","article-title":"Patient reported outcomes in a practice changing randomized trial of bevacizumab in the treatment of advanced cervical cancer: an NGR Oncology\/Gynecologic Oncology Group Study","volume":"16","author":"Penson","year":"2015","journal-title":"Lancet Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0133|cit133","first-page":"23","article-title":"Changing paradigms in the systemic treatment of advanced cervical cancer","volume":"214","author":"Pfaendler","year":"2016","journal-title":"Expert Reviews Gynecology"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/PPO.0000000000000324","article-title":"Bevacizumab in cervical cancer: 5 years after","volume":"24","author":"Pfaendler","year":"2018","journal-title":"Cancer Journal"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0135|cit135","first-page":"1","article-title":"Primary cervical screening with high risk human papillomavirus testing: observational study","volume":"364","author":"Rebolj","year":"2019","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0136|cit136","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/IGC.0000000000001000","article-title":"Systematic review and network meta-analysis of bevacizumab plus first-line topotecan-paclitaxel or cisplatin-paclitaxel versus non-bevacizumab-containing therapies in persistent, recurrent, or metastatic cervical cancer","volume":"27","author":"Rosen","year":"2017","journal-title":"International Journal of Gynecological Cancer"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jjco\/hyp117","article-title":"A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group\/Japan Clinical Oncology Group Study (JCOG0505)","volume":"40","author":"Saito","year":"2010","journal-title":"Japanese Journal of Clinical Oncology"},{"issue":"10","key":"10.1002\/14651858.CD013348.pub2-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006469.pub2","article-title":"Chemotherapy for metastatic and recurrent cervical cancer","author":"Scatchard","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2011.10.060","article-title":"A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417","volume":"83","author":"Schefter","year":"2012","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2013.10.022","article-title":"RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma","volume":"88","author":"Schefter","year":"2014","journal-title":"International Journal of Radiation Oncology Biology Physics"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bjc.2017.400","article-title":"Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology\/Gynaecologic Oncology Group Study","volume":"118","author":"Seamon","year":"2018","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0143|cit143","unstructured":"Shemilt I Mugford M Byford S Drummond M Eisenstein E Knapp M Chapter 15. Incorporating economics evidence. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0144|cit144","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0145|cit145","first-page":"800","article-title":"Demonstration and characterization of the angiogenic properties of cervical dysplasia","volume":"54","author":"Smith-McCune","year":"1994","journal-title":"Cancer Research"},{"issue":"4","key":"10.1002\/14651858.CD013348.pub2-BIB0146|cit146","first-page":"872","article-title":"Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin","volume":"39","author":"Takano","year":"2013","journal-title":"Journal of Obstetrics and Gynaecology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013348.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1093\/annonc\/12.suppl_3.S7","article-title":"Health-related quality of life measures in cancer","volume":"12","author":"Tamburini","year":"2001","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0148|cit148","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007958.pub2","article-title":"Angiogenesis-inhibitors for metastatic thyroid cancer","author":"Tan","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD013348.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11912-005-0007-z","article-title":"Gynaecological group trials of chemotherapy for metastatic and recurrent cervical cancer","volume":"7","author":"Tewari","year":"2005","journal-title":"Current Oncology Reports"},{"issue":"21","key":"10.1002\/14651858.CD013348.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-14-1099","article-title":"New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy","volume":"20","author":"Tewari","year":"2014","journal-title":"Clinical Cancer Research"},{"issue":"10103","key":"10.1002\/14651858.CD013348.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0002-9378(99)70492-8","article-title":"Angiogenesis in cervical intraepithelial neoplasia and the risk of recurrence","volume":"181","author":"Tjalma","year":"1999","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.2147\/OTT.S68286","article-title":"Angiogenesis and antiangiogenic agents in cervical cancer","volume":"7","author":"Tomao","year":"2014","journal-title":"OncoTargets and Therapy"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0154|cit154","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"10","key":"10.1002\/14651858.CD013348.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1084\/jem.20181617","article-title":"Kidney cancer: the next decade","volume":"215","author":"Turajlic","year":"2018","journal-title":"Journal of Experimental Medicine"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(03)13778-6","article-title":"Cervical cancer","volume":"361","author":"Waggoner","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013348.pub2-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005392.pub3","article-title":"Anti-angiogenic therapies for metastatic colorectal cancer","author":"Wagner","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013348.pub2-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008941.pub2","article-title":"Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer","author":"Wagner","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"9","key":"10.1002\/14651858.CD013348.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1517\/13543784.2013.812071","article-title":"Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment","volume":"22","author":"Wei","year":"2013","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0160|cit160","unstructured":"Welsh Cancer Intelligence and Surveillance Unit Cancer incidence 2001-2017 www.wcisu.wales.nhs.uk"},{"issue":"7","key":"10.1002\/14651858.CD013348.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1586\/era.09.58","article-title":"Cervical cancer therapy: current, future and anti-angiogenesis targeted treatment","volume":"9","author":"Willmott","year":"2009","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1002\/14651858.CD013348.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2006.03.023","article-title":"Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer","volume":"103","author":"Wright","year":"2006","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD013348.pub2-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2012.04.007","article-title":"Molecularly targeted therapies in cervical cancer. A systematic review","volume":"126","author":"Zagouri","year":"2012","journal-title":"Gynecologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD013348.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ygyno.2013.04.009","article-title":"Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer","volume":"130","author":"Zighelboim","year":"2013","journal-title":"Gynecologic Oncology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T11:20:41Z","timestamp":1639221641000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013348.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":164,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013348.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]}}}